2003, Number 6
<< Back Next >>
Gac Med Mex 2003; 139 (6)
Type 2 Neurofibromatosis
Carrillo-Esper R, Cruz SMA, Calvo-Carrillo B, Paredes-Fernández M
Language: Spanish
References: 7
Page: 623-624
PDF size: 316.95 Kb.
Text Extraction
No abstract
REFERENCES
Morrison H, Sherman LS, Legg J, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001;15:968-980.
Shaw RJ, Paez JG, Curto M, et al. The Nf2 tumor suppressor, merlin functions in Tac-dependent signaling. Dev Cell 2001;1:63-72.
Baser ME, Evans R, Gareth D, Gutmann DH. Neurofibromatosis 2. Curr Opin Neurol 2003;16:27-33.
Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. Neurofibromatosis 2 (INF2): clinical characteristics of 63 affected individuais and clinical evidence for heterogeneity. Am J Med Genet 1994; 52:450-461.
Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging' and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38:880-885.
Evans DG. Neurofibromatosis type 2: genetic and clinical features. ENT-Ear Nose Throat J 1999;78:97-100.
Andrews DW, Suárez O, Goidman HW, et al. Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of acoustic schwannomas: comparative observations of 125 patients treated at one institution. Int J Radiat Oncol Biol Phys 2001;50:1265-1278.
Full text